• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis.
【24h】

Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis.

机译：2型糖尿病中短效胰岛素类似物与常规人胰岛素的比较：荟萃分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: Short-acting insulin analogues, in comparison with regular human insulin (HRI), provide a greater control of postprandial glucose, while their superiority on haemoglobin A1c (HbA1c) is controversial. METHOD: All randomized controlled trials (RCTs) with a duration >4 weeks comparing short-acting insulin analogues (lispro, aspart or glulisine) with HRI in type 2 diabetic patients were retrieved; data on HbA1c and postprandial glucose et end-point and incidence of severe hypoglycaemia were extracted and meta-analysed. RESULTS: A total of 13 RCTs (7, 4 and 2 with lispro, aspart and glulisine, respectively) were retrieved and included in the analysis. Short-acting analogues reduced HbA1c by 0.4% (0.1-0.6%) (p = 0.027) in comparison with HRI. A significant improvement was observed also in self-monitored 2 h postbreakfast and dinner blood glucose. The overall rate of severe hypoglycaemia was not significantly different with short-acting analogues and HRI [Mantel-Haenszel odds ratio for 95% confidence interval 0.61 (0.25-1.45)]. CONCLUSION: In type 2 diabetic patients, short-acting insulin analogues provide a better control of HbA1c and postprandial glucose than regular human insulin, without any significant reduction of the risk of severe hypoglycaemia.
机译：目的：与常规人胰岛素（HRI）相比，短效胰岛素类似物可更好地控制餐后血糖，而它们对血红蛋白A1c（HbA1c）的优越性尚有争议。方法：检索所有持续时间超过4周的随机对照试验（RCT），该试验比较了2型糖尿病患者中短效胰岛素类似物（赖脯，天冬氨酸或甘氨酸）与HRI的关系。提取和荟萃分析HbA1c和餐后血糖的数据以及终点和严重低血糖的发生率。结果：共检索到13个RCT（分别为lispro，aspart和glulisine的7个，4个和2个），并将其包括在分析中。与HRI相比，短效类似物使HbA1c降低了0.4％（0.1-0.6％）（p = 0.027）。早餐后2小时自我监测和晚餐血糖水平也得到了显着改善。短效类似物和HRI的严重低血糖的总发生率无显着差异[95％置信区间0.61（0.25-1.45）的Mantel-Haenszel比值比]。结论：在2型糖尿病患者中，短效胰岛素类似物比普通人胰岛素可更好地控制HbA1c和餐后葡萄糖，而不会严重降低严重低血糖的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号